The Latest Cardiac and Vascular News
Westport, CT, Nov. 26, 2019 (GLOBE NEWSWIRE) — ·New areas of collaboration identified between Mayo Clinic and BioSig ·Focus on previously untapped arrhythmia treatments ·Additional development areas covering novel therapies for autonomic nervous system disease BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a […]
VANCOUVER, CA, and BERLIN, DE, Nov. 26, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that […]
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]
Continued Increase in Revenues and Strong Balance Sheet MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlights and financial results for the first quarter ended September 30, 2019. Mesoblast Chief Executive Dr Silviu Itescu stated: “The Company’s financial results for […]
CALGARY, Alberta, Nov. 25, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company. The Incentive Program does not apply to warrants held by […]
On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its […]
– Third Quarter Revenues Increase 33% to $8.1 Million – – WatchPAT™ Revenues Increase 32% in the Third Quarter to $7.6 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – CAESAREA, Israel, Nov. 26, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: […]
LOS ANGELES–(BUSINESS WIRE)–OTITOPIC – A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the successful conclusion based on PD results of a clinical trial for its lead drug: Dry Powder Inhalation […]
The redesigned Eko CORE boasts active noise cancellation, sleeker design, and powerful software to allow medical professionals to more effectively screen for heart disease San Francisco, CA, Nov. 25, 2019 (GLOBE NEWSWIRE) — Eko, a digital health company with an AI-powered cardiac screening platform, today announced the second generation of its CORE […]
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1 First-in-class siRNA biological mechanism enables unique twice-yearly, subcutaneous dosing regimen and seamless integration into […]
